Life on Ibrance Long-term
Life on Ibrance Long-term
Visiting US oncologist and professor Adam Brufsky shares his knowledge on what long-term treatment with Ibrance looks like.
Ibrance is a CDK4/6 inhibitor widely used to treat advanced ER+ breast cancer.
In this webinar, Professor Brufsky discusses what patients and their medical team need to consider with long-term use of Ibrance (two years or more), including side effects and dose changes. He also shares an international perspective of treating patients with Ibrance.
Join us online at lunchtime on 13 November and don't forget your questions for the Q&A at the end!
Our previous webinar, Life on Ibrance, told you what you needed to know if you were just getting started on the drug.
Meet our panel
Professor Adam Brufsky is a medical oncologist, a professor of medicine at the University of Pittsburgh School of Medicine and the associate director of clinical investigation for the University of Pittsburgh Cancer Institute in Pennsylvania, USA. He will talk about long-term treatment with Ibrance and what factors need to be considered as well as sharing some of his real world experience.